Taysha Gene Therapies, Inc. Operating Cash Flow
Taysha Gene Therapies, Inc. (TSHA) reported Operating Cash Flow of -$81.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Taysha Gene Therapies, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$40.42M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$40.88M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$26.72M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$24.17M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$93.09M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$81.22M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$73.02M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$88.39M.
| Period end | Net Cash Provided by (Used in) Operating Activities 0 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$40.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$81.30M 10-Q · filed 2026-08-11 | -$108.03M derived: sum of 3 quarters · filed 2026-08-11 | -$132.19M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$40.88M 10-Q · filed 2026-05-06 | -$67.60M derived: sum of 2 quarters · filed 2026-05-06 | -$91.77M derived: sum of 3 quarters · filed 2026-05-06 | -$111.95M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$26.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$50.89M derived: sum of 2 quarters · filed 2026-03-19 | -$71.07M derived: sum of 3 quarters · filed 2026-08-11 | -$93.09M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | -$24.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$44.35M derived: sum of 2 quarters · filed 2026-08-11 | -$66.37M 10-Q · filed 2025-11-04 | -$84.68M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$20.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$42.20M 10-Q · filed 2026-08-11 | -$60.51M derived: sum of 3 quarters · filed 2026-08-11 | -$82.13M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$22.02M 10-Q · filed 2026-05-06 | -$40.33M derived: sum of 2 quarters · filed 2026-05-06 | -$61.94M derived: sum of 3 quarters · filed 2026-05-06 | -$83.45M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$18.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$39.92M derived: sum of 2 quarters · filed 2026-03-19 | -$61.43M derived: sum of 3 quarters · filed 2026-03-19 | -$81.22M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | -$21.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$43.12M derived: sum of 2 quarters · filed 2025-11-04 | -$62.92M 10-Q · filed 2025-11-04 | -$79.03M derived: sum of 4 quarters · filed 2025-11-04 | ||||
| 2024-06-30 | -$21.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$41.30M 10-Q · filed 2025-08-12 | -$57.42M derived: sum of 3 quarters · filed 2025-08-12 | -$75.37M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$19.80M 10-Q · filed 2025-05-15 | -$35.91M derived: sum of 2 quarters · filed 2025-05-15 | -$53.86M derived: sum of 3 quarters · filed 2025-05-15 | -$72.63M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$16.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$34.07M derived: sum of 2 quarters · filed 2025-02-26 | -$52.83M derived: sum of 3 quarters · filed 2025-02-26 | -$73.02M 10-K · filed 2025-02-26 | ||||
| 2023-09-30 | -$17.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$36.72M derived: sum of 2 quarters · filed 2024-11-13 | -$56.90M 10-Q · filed 2024-11-13 | -$42.19M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$18.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$38.95M 10-Q · filed 2024-08-12 | -$24.24M derived: sum of 3 quarters · filed 2024-08-12 | -$53.05M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | -$20.18M 10-Q · filed 2024-05-14 | -$5.47M derived: sum of 2 quarters · filed 2024-05-14 | -$34.28M derived: sum of 3 quarters · filed 2024-05-14 | -$67.64M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $14.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$14.10M derived: sum of 2 quarters · filed 2024-03-19 | -$47.45M derived: sum of 3 quarters · filed 2024-03-19 | -$88.39M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | -$28.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$62.16M derived: sum of 2 quarters · filed 2023-11-14 | -$103.10M 10-Q · filed 2023-11-14 | -$102.67M 10-Q · filed 2022-11-08 | -$143.36M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | -$33.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$74.29M 10-Q · filed 2023-08-14 | -$74.01M 10-Q · filed 2022-08-11 | -$114.55M derived: sum of 3 quarters · filed 2023-08-14 | -$146.48M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$40.94M 10-Q · filed 2023-05-11 | -$40.80M 10-Q · filed 2022-05-16 | -$81.20M derived: sum of 2 quarters · filed 2023-05-11 | -$113.13M derived: sum of 3 quarters · filed 2023-05-11 | -$135.95M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$40.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$72.19M derived: sum of 2 quarters · filed 2023-03-28 | -$95.01M derived: sum of 3 quarters · filed 2023-03-28 | -$117.04M 10-K · filed 2023-03-28 | ||||
| 2021-09-30 | -$31.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$54.75M derived: sum of 2 quarters · filed 2022-11-08 | -$76.78M 10-Q · filed 2022-11-08 | -$96.63M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$22.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$44.85M 10-Q · filed 2022-08-11 | -$64.70M derived: sum of 3 quarters · filed 2022-08-11 | -$71.42M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$22.04M 10-Q · filed 2022-05-16 | -$41.88M derived: sum of 2 quarters · filed 2022-05-16 | -$48.60M derived: sum of 3 quarters · filed 2022-05-16 | -$51.06M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | -$19.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$26.56M derived: sum of 2 quarters · filed 2022-03-31 | -$29.03M derived: sum of 3 quarters · filed 2022-03-31 | -$30.73M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$6.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$9.18M derived: sum of 2 quarters · filed 2021-11-10 | -$10.88M 10-Q · filed 2021-11-10 | -$10.88M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | -$2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$4.17M 10-Q · filed 2021-08-16 | -$4.17M derived: sum of 3 quarters · filed 2021-08-16 | |||||
| 2020-03-31 | -$1.70M 10-Q · filed 2021-05-11 | -$1.70M derived: sum of 2 quarters · filed 2021-05-11 | ||||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 | |||||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |